StockData
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Adaptive Biotechnologies Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)

Close on Oct 19, 2026

Market cap
$3.83B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026After market close$71.60M––
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026After market close$70.90M––
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026Before market open$72.00M––
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025After market close$94.00M––
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025After market close$58.90M––
Q1 FY2025
Ended Mar 31, 2025
May 1, 2025After market close$52.40M$-0.20–
Q4 FY2024
Ended Dec 31, 2024
Feb 11, 2025After market close$47.50M––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close$46.40M––
Q2 FY2024
Ended Jun 30, 2024
Aug 1, 2024After market close$43.20M$-0.31–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Feb 14, 2024After market close–––

Company guidance

Outlook given with results on Jul 29, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
MRD revenue annual growthfull year 202626% to 31% growthNew
total company operating expenses, including cost of revenuefull year$350.00M to $355.00MLowered
MRD revenuefull year$268.00M to $278.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Adaptive Biotechnologies filed with the SEC